Why the study?
Does the aldosterone synthase (CYP11B2) -344 C/T polymorphism affect the blood pressure-lowering response to irbesartan or atenolol in patients with hypertension and left ventricular hypertrophy?
Does the aldosterone synthase (CYP11B2) -344 C/T polymorphism affect the blood pressure-lowering response to irbesartan or atenolol in patients with hypertension and left ventricular hypertrophy?
The aldosterone synthase -344 C/T polymorphism is associated with the systolic blood pressure-lowering response to irbesartan, with the TT genotype showing the greatest reduction.
No takes yet. Share an insight, caveat, or question.
May support CYP11B2 TT-guided irbesartan preference in LVH hypertension; extends pharmacogenetic RCT findings on ARB response.
Kurland et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: